Evidence map›Paper›PMID 39854311›Full record

ArticlePloS one2025

Activation of S1PR2 on macrophages and the hepatocyte S1PR2/RhoA/ROCK1/MLC2 pathway in vanishing bile duct syndrome.

Aya Miyagawa-Hayashino, Tetsuya Imura, Toshiaki Takezawa, Maki Hirai, Saya Shibata, Hiroshi Ogi, Takahiro Tsujikawa, Eiichi Konishi

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Bile acid signaling in health and disease.Molecular biomedicine · 2026
    Review
  2. Article
  3. Biological Actions of Bile Acids via Cell Surface Receptors.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aya Miyagawa-HayashinoDepartment of Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID 0009-0002-8679-4800
Tetsuya ImuraDepartment of Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Toshiaki TakezawaFaculty of Pharmacy, Chiba Institute of Science, Chiba, Japan.
Maki HiraiDepartment of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Saya ShibataDepartment of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroshi OgiDepartment of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takahiro TsujikawaDepartment of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID 0000-0003-1647-342X
Eiichi KonishiDepartment of Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunologic bile duct destruction is a pathogenic condition associated with vanishing bile duct syndrome (VBDS) after liver transplantation and hematopoietic stem-cell transplantation. As the bile acid receptor sphingosine 1-phosphate receptor 2 (S1PR2) plays a critical role in recruitment of bone marrow-derived monocytes/macrophages to sites of cholestatic liver injury, S1PR2 expression was examined using cultured macrophages and patient tissues. Bile canaliculi destruction precedes intrahepatic ductopenia; therefore, we focused on hepatocyte S1PR2 and the downstream RhoA/Rho kinase 1 (ROCK1) signaling pathway and bile canaliculi alterations using three-dimensional hepatocyte culture models that form obvious bile canaliculus-like networks. Multiplex immunohistochemistry revealed increased numbers of S1PR2+CD45+CD68+FCN1+ inflammatory macrophages and S1PR2+CD45+CD68+MARCO+ Kupffer cells in liver tissues showing ductopenia due to graft-versus-host disease and rejection post-liver transplant compared with normal liver. Macrophage expression of proinflammatory cytokines, including MCP1, was reduced following S1PR2 inhibition. Taurocholic acid and S1P2 agonist induced hepatocyte S1PR2 and reduced RhoA/ROCK1 expression, resulting in bile canaliculi dilatation. S1PR2 inhibition reversed the effect on RhoA/ROCK1 expression, resulting in maintenance of bile canaliculi through myosin light chain 2 (MLC2) phosphorylation. Activation of S1PR2 on macrophages and S1PR2 on hepatocytes may disrupt bile canaliculi dynamics in VBDS under regulation by RhoA/ROCK1 through MLC2 phosphorylation.

Indexed as

Bile Duct DiseasesCardiac MyosinsHepatocytesMacrophagesMyosin Light ChainsReceptors, LysosphingolipidrhoA GTP-Binding Proteinrho-Associated KinasesFemaleHumansMaleMiddle AgedSignal TransductionSphingosine-1-Phosphate ReceptorsCardiac Myosinsmyosin light chain 2Myosin Light ChainsReceptors, LysosphingolipidrhoA GTP-Binding ProteinRHOA protein, humanrho-Associated KinasesROCK1 protein, humanS1PR2 protein, humanSphingosine-1-Phosphate Receptors

Identifiers

PMID39854311
PMCPMC11760576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.